Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial
ClinicalTrials.gov NCT05367063 FUNDING: This study was financially supported by the National Key Research and Development programme (2023YFA1802000), the National Natural Science Foundation of China (Youth Fund 82200909), the Young and Middle-aged Diabetes project from the Bethune Foundation (Z04JKM2022E002), the Joint Research Development project between Shenkang and United Imaging on Clinical Research and Translation (SKLY2022CRT201), the Shanghai Municipal 'Explorer plan' (the second batch) project in 2024 (24TS1411000) and the Shanghai pujiang programme (21PJD012).
Authors
- Yinyin Chen (ORCID: https://orcid.org/0009-0002-5034-404X)
- Xinxia Chang (ORCID: https://orcid.org/0000-0001-8276-5266)
- Mengsu Zeng (ORCID: https://orcid.org/0009-0004-5230-8012)
- Xiaoying Li
- Jiaojiao Liu
- Shuangshuang Chen
- Ying Chen
- Hang Jin
- Hongmei Yan
- Zhitian Zhang
Institutions
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shanghai Institute of Hematology (CN)
Publication Details
- Journal
- Diabetologia
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1007/s00125-026-06682-w
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Fudan University